Vector Biosystems

At Excision BioTherapeutics our mission is to provide the finest gene editing therapeutics to improve the lives of chronically ill patients. Our focus is to develop targeted biologics that safely eradicate viruses from infected individuals.

Carisma Therapeutics Inc. is a Philadelphia-based biotech company that is revolutionizing cancer treatment through the development of CAR-Macrophages, a groundbreaking approach to immunotherapy. By engineering monocytes and macrophages to attack tumors, Carisma's innovative cellular therapies have the potential to deliver long-term anti-tumor immunity and significantly improve patient outcomes. With a focus on leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy, Carisma's unique therapeutic approach engages both the innate and adaptive immune systems to launch a multi-pronged attack on tumors. By addressing key challenges faced by current cell therapies, such as tumor infiltration, immunosuppressive tumor microenvironments, and antigen heterogeneity, Carisma is at the forefront of developing life-changing treatments for patients with cancer and other serious disorders.Generated from the website

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo's cellular therapy, known as KIR-CAR, is designed to provide a natural stimulation to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.